PPT-Selecting Direct Oral Anticoagulants and Reversal Agents

Geno J Merli MD MACP FSVM FHM Professor Medicine amp Surgery Sidney Kimmel Medical College Thomas Jefferson University Hospitals Disclosures Geno J Merli MD Research Grant BMSPfizer ADIOS study completed 122019 Presented ACC Meeting 32019. Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. Nothing to disclose. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. (. N. OAC). Dan . Moellentin. , . PharmD. , BCPS, Associate Professor . Husson. University. Strokes in Atrial Fibrillation. 1/5 of strokes are caused by a. fib. 1/3 cardiac arrhythmias hospitalizations . Northlakes. Community Clinic. Minong, WI. Novel Anticoagulants:. Who Needs an INR Anymore?. Apixaban. (. Eliquis. ):. Approved in 2014. Rivaroxaban. (. Xarelto. ):. Approved in 2011. Dabigatran. (. We Now?. Moderator. Christian T. Ruff, MD, MPH. Assistant Professor of Medicine. TIMI Study Group. Brigham and . Women's . Hospital. Harvard Medical School. Boston, Massachusetts. Arash Afshinnik, MD. R2 Patcharee Seesongsom. R2 . Sirada. . Phojai. Advisor AJ . T. a. chawan. . J. iratiwanon. Scope. Overview. Introduction of NOACs. Rivaroxaban. ( . Xarelto. ). Dabigatran. ( . Pradaxa. ). Fawaz Altuwaijri. ACEM trainee. Introduction. Characteristics . of novel . anticoagulants. Laboratory Testing. Reversal in the bleeding patient. Introduction. Prevalence . atrial fibrillation. . 3.03 million in 2005. Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Program Goals. ERAS Definition. Achieving ERAS. Goals of ERAS. Anesthesia Roles in ERAS. NMB and Reversal as an Element . of ERAS. Purpose of NMB and Types of NMBAs. Nondepolarizing NMBA Reversal. PRNB. Introduction/Overview . VKA-Associated Bleeding: . Results From the RADOA Registry . Reversal Agents for VKA-Associated Anticoagulation. Management of Urgent Anticoagulation Reversal: . 4F-PCC vs FFP. Management of Anticoagulants & Antiplatelet Agents Pre and Post Endoscopy Thomas Savides, M.D. Professor of Clinical Medicine University of California, San Diego Disclosures None Learning Objectives Dr Than . Kyaw. 27 February 2012. COAGULATION. Complex process of blood clotting. Important part of . hemostasis. Cessation of blood loss from damaged vessel(s). Disorders of coagulation can lead to an increased risk of bleeding (hemorrhage) or clotting (thrombosis). . This presentation is based on the . December 2013. AHRQ WebM&M Spotlight Case. See the full article at . http://webmm.ahrq.gov. . CME credit is available. Commentary by: . Margaret . C. Fang. , MD, MPH, University of California, San Francisco. By:. . Akash Saxena. KLE . College of Pharmacy, . Belagavi. A constituent Unit of KLE Academy of Higher Education and Research. Nehru Nagar, . Belagavi. . –. 590 010, Karnataka, India. Phone:. 0831-2471399;. Content. : Eljim Tesoro, PharmD, BCCCP, FNCS, FCCM;. Mehrnaz Pajoumand, PharmD . Slides. : Eljim Tesoro, PharmD, BCCCP, FNCS, FCCM .  .  .  .  . Editors’ Note: Global Considerations. The intent of the editors, authors, and reviewers of this ENLS topic was not to address all the variations in international practice for the different diseases. We have discussed major practice variances (e.g., the availability of diagnostic testing, or the type of medications used) and encourage learners to use the ENLS algorithms as a framework on which any relevant local practice guidelines can be incorporated..